目的:探讨Philips Big Bore CT模拟定位机配合强化扫描技术在三维适形放疗中的应用价值。方法:115例患者应用Philips Big Bore CT模拟定位机和安科公司ASA-200高压注射器,使用非离子造影剂进行强化扫描,全程由主管医生陪护。结果:115例...目的:探讨Philips Big Bore CT模拟定位机配合强化扫描技术在三维适形放疗中的应用价值。方法:115例患者应用Philips Big Bore CT模拟定位机和安科公司ASA-200高压注射器,使用非离子造影剂进行强化扫描,全程由主管医生陪护。结果:115例患者顺利完成CT模拟定位强化扫描,与CT平扫相比良好地显示了肿瘤区(GTV),满足三维适形放疗或三维适形调强放疗精确勾画靶区的要求。结论:三维适形放疗时应用Philips Big Bore CT模拟定位机是完成各种复杂被动体位及同步固定模具扫描的基本保证,同时配合使用高压注射器强化扫描技术是精确勾画肿瘤区(GTV)、提高肿瘤放疗治愈率的有效措施之一。展开更多
Objective: To determine the possible therapeutic gain of using three-dimensional conformal radiotherapy (3D-CRT) as a treatment option for portal vein tumor thrombus (PVTT) in patients with hepatocellular carcinoma (H...Objective: To determine the possible therapeutic gain of using three-dimensional conformal radiotherapy (3D-CRT) as a treatment option for portal vein tumor thrombus (PVTT) in patients with hepatocellular carcinoma (HCC) and to evaluate the tolerance and toxicity of using such treatment. Materials and methods: Sixty two patients were enrolled in this prospective study between June 2013 and August 2015. The clinical target volume (CTV) was the PVTT and the prescribed dose was 50 Gy/25 fractions. The median follow-up time was 7.4 months. Results: The thrombus crude response rate was 40.4% and the only significant prognostic factor for response was the thrombus size. Responders had significant better survival compared to non-responders with a median survival of 12.5 and 8 months respectively (P Conclusions: The results of this study suggest that radiotherapy should be considered as a safe treatment option for HCC patients with PVTT. It is effective not only for PVTT local control but also for survival, although prospective randomized trials are needed to confirm these results.展开更多
<strong>Context:</strong> <span><span><span><span><span style="font-family:""><span style="font-family:Verdana;">Technological advances have imp...<strong>Context:</strong> <span><span><span><span><span style="font-family:""><span style="font-family:Verdana;">Technological advances have improved the toxicities of radiotherapy. We are evaluating the 3D technique in prostate cancer. </span><b><span style="font-family:Verdana;">Materials and Methods:</span></b><span style="font-family:Verdana;"> Retrospective study from January 2015 to December 2015 with 29 files. Survival was calculated by Kaplan-Meier method. </span><b><span style="font-family:Verdana;">Results: </span></b><span style="font-family:Verdana;">We collected 29 patient records over the study period. The median age was 75 years with the following extremes: 54 years and 83 years. The median PSA level was 12 ng/ml with a range of 3.05 to 79 ng/ml. Gleason score analysis showed 6 patients (20.69%) with a score of 6 (3 + 3), 23 patients (79.31%) with a score of 7 including 12 patients (41.38%) with grade 3 and 11 patients (37.93%) with grade 4. The median dose delivered was 74 Gy, with a mean dose of 73.79 Gy and extremes of 70 Gy for the minimum and 76 Gy for the maximum. Hormone therapy was combined with radiotherapy in 17 patients (58.62%). Sev</span><span style="font-family:Verdana;">en patients (24.14%) had grade 1 acute bladder toxicity and one patient</span><span style="font-family:Verdana;"> (3.45%) </span><span style="font-family:Verdana;">had grade 2 acute toxicity. Late bladder toxicity was grade 1 in 5 patients</span><span style="font-family:Verdana;"> (17.24%), grade 2 in 3 patients (10.34%) and grade 3 in 1 patient (3.45%). </span><span style="font-family:Verdana;">Late rectal toxicity, grade 2 in 3 patients (10.34%), grade 3 in 1 patient, was noted. Overall survival at 2 years was 100% and 89.65% at 5 years. Relapse-free </span><span><span style="font-family:Verdana;">survival at 2 years was 82.76% and 62.07% at 5 years. There were 3 deaths (10.34%) of which only one was related to prostate cancer. </span><b><span style="font-family:Verdana;">Conclusion:</span></b></span></span></span><展开更多
文摘目的:探讨Philips Big Bore CT模拟定位机配合强化扫描技术在三维适形放疗中的应用价值。方法:115例患者应用Philips Big Bore CT模拟定位机和安科公司ASA-200高压注射器,使用非离子造影剂进行强化扫描,全程由主管医生陪护。结果:115例患者顺利完成CT模拟定位强化扫描,与CT平扫相比良好地显示了肿瘤区(GTV),满足三维适形放疗或三维适形调强放疗精确勾画靶区的要求。结论:三维适形放疗时应用Philips Big Bore CT模拟定位机是完成各种复杂被动体位及同步固定模具扫描的基本保证,同时配合使用高压注射器强化扫描技术是精确勾画肿瘤区(GTV)、提高肿瘤放疗治愈率的有效措施之一。
文摘Objective: To determine the possible therapeutic gain of using three-dimensional conformal radiotherapy (3D-CRT) as a treatment option for portal vein tumor thrombus (PVTT) in patients with hepatocellular carcinoma (HCC) and to evaluate the tolerance and toxicity of using such treatment. Materials and methods: Sixty two patients were enrolled in this prospective study between June 2013 and August 2015. The clinical target volume (CTV) was the PVTT and the prescribed dose was 50 Gy/25 fractions. The median follow-up time was 7.4 months. Results: The thrombus crude response rate was 40.4% and the only significant prognostic factor for response was the thrombus size. Responders had significant better survival compared to non-responders with a median survival of 12.5 and 8 months respectively (P Conclusions: The results of this study suggest that radiotherapy should be considered as a safe treatment option for HCC patients with PVTT. It is effective not only for PVTT local control but also for survival, although prospective randomized trials are needed to confirm these results.
文摘<strong>Context:</strong> <span><span><span><span><span style="font-family:""><span style="font-family:Verdana;">Technological advances have improved the toxicities of radiotherapy. We are evaluating the 3D technique in prostate cancer. </span><b><span style="font-family:Verdana;">Materials and Methods:</span></b><span style="font-family:Verdana;"> Retrospective study from January 2015 to December 2015 with 29 files. Survival was calculated by Kaplan-Meier method. </span><b><span style="font-family:Verdana;">Results: </span></b><span style="font-family:Verdana;">We collected 29 patient records over the study period. The median age was 75 years with the following extremes: 54 years and 83 years. The median PSA level was 12 ng/ml with a range of 3.05 to 79 ng/ml. Gleason score analysis showed 6 patients (20.69%) with a score of 6 (3 + 3), 23 patients (79.31%) with a score of 7 including 12 patients (41.38%) with grade 3 and 11 patients (37.93%) with grade 4. The median dose delivered was 74 Gy, with a mean dose of 73.79 Gy and extremes of 70 Gy for the minimum and 76 Gy for the maximum. Hormone therapy was combined with radiotherapy in 17 patients (58.62%). Sev</span><span style="font-family:Verdana;">en patients (24.14%) had grade 1 acute bladder toxicity and one patient</span><span style="font-family:Verdana;"> (3.45%) </span><span style="font-family:Verdana;">had grade 2 acute toxicity. Late bladder toxicity was grade 1 in 5 patients</span><span style="font-family:Verdana;"> (17.24%), grade 2 in 3 patients (10.34%) and grade 3 in 1 patient (3.45%). </span><span style="font-family:Verdana;">Late rectal toxicity, grade 2 in 3 patients (10.34%), grade 3 in 1 patient, was noted. Overall survival at 2 years was 100% and 89.65% at 5 years. Relapse-free </span><span><span style="font-family:Verdana;">survival at 2 years was 82.76% and 62.07% at 5 years. There were 3 deaths (10.34%) of which only one was related to prostate cancer. </span><b><span style="font-family:Verdana;">Conclusion:</span></b></span></span></span><
